Clinical trials: Controlled Diabetes
Schizophrenia
A Placebo-Controlled, Cross-Over Trial of Aripiprazole
This study is a ten-week, placebo-controlled, double-blind, cross-over, randomized trial of the novel antipsychotic agent, aripiprazole, added to 20 obese stable olanzapine-treated patients with schizophrenia or schizoaffective…
- Trial name
- NCT00351936
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Diabetes Mellitus, Type 2, Hypertension
24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
This trial is designed to investigate the efficacy and safety of empagliflozin compared with placebo in hypertensive black/African Americans with type 2 Diabetes Mellitus.
- Trial name
- NCT02182830
- Testing
- Empagliflozin low dose, Empagliflozin high dose
- Where
- 92 sites in United States
- Volunteers
- 166 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
This is a study in Chinese adults with type 2 diabetes. The study is open to people who take insulin but still have too high blood sugar levels. Participants may additionally be taking up to 2 other medicines for their diabetes.
- Trial name
- NCT04233801
- Testing
- Empagliflozin
- Where
- 24 sites in China
- Volunteers
- 219 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes
Group Visits for High Risk Type 1 Diabetes (T1D)
The investigators propose to conduct a pilot prospective cohort study to assess the impact of shared medical appointments (SMA) visits in underserved youth with poorly controlled type 1 diabetes (T1D).
- Trial name
- NCT05431686
- Testing
- SMA visits
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Children's National Research Institute
Diabetes Mellitus, Type 2
Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Type II Diabetes
The aim of this pilot study is to assess the safety and preliminary efficacy of 5-ALA - SFC at doses up to 200 mg per day in subjects with type II diabetes.
- Trial name
- NCT02481141
- Testing
- 5-ALA-SFC
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- SBI Pharmaceuticals Co, Ltd.
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the effect on glycaemic control of liraglutide or exenatide when added to subject's ongoing OAD (oral anti-diabetic…
- Trial name
- LEAD-6 (NCT00518882)
- Testing
- liraglutide, exenatide
- Where
- 125 sites in United States, Austria and 14 more
- Volunteers
- 467 people
- Sponsor
- Novo Nordisk A/S
Hypercholesterolemia, Diabetes Mellitus, Type 2
Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)
This multicenter, randomized, double-blind, placebo-controlled study will assess, after 6 weeks of dosing, whether co-administration of ezetimibe 10 mg with simvastatin 20 mg will be more effective than treatment with doubling…
- Conditions
- Hypercholesterolemia, Diabetes Mellitus, Type 2, Coronary Disease
- Trial name
- NCT00423488
- Testing
- Ezetimibe 10 mg, Simvastatin 20 mg
- Volunteers
- 93 people
- Sponsor
- Organon and Co
Type 2 Diabetes Mellitus
A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes
The purposes of this study is to evaluate the efficacy and safety of SYR-472 when administered at a dose of 100 mg once weekly as an add-on to insulin therapy compared with placebo in patients with type 2 diabetes mellitus and…
- Trial name
- NCT02324569
- Testing
- SYR-472
- Where
- 65 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Takeda
Type 1 Diabetes
Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)
A prospective, single-arm study of 13 weeks of home use of the t:slim X2 insulin pump with Control-IQ technology in individuals with type 1 diabetes who will plan to use at least one basal rate > 3 units/hr.
- Trial name
- NCT05422053
- Testing
- t:slim X2 insulin pump with Control-IQ technology 1.5
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes, Obesity
A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
This study will assess tolerability, safety, and pharmacodynamics (PD) of twice daily (BID) administration of PF- 06882961 in adult participants with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin and in…
- Trial name
- NCT04617275
- Testing
- PF-06882961
- Where
- 38 sites in United States
- Volunteers
- 151 people
- Sponsor
- Pfizer
Type1 Diabetes
Neural-net Artificial Pancreas (NAP)
This study is intended to assess a Neural-net Artificial Pancreas (NAP) implementation of an established AP controller - the University of Virginia Model Predictive Control Algorithm (UMPC).
- Trial name
- NAP (NCT05876273)
- Testing
- Neural-net Artificial Pancreas, University of Virginia Model Predictive Control
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Virginia
Diabetes, Insulin Resistance
Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV
We will test the safety of a new class of anti-diabetes compounds (DPPIV-inhibitors) in people living with HIV. Future trials will examine efficacy for treating diabetes and reducing cardiovascular disease risk in people living…
- Trial name
- DPPIVinHIV (NCT01093651)
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Obesity
Sugar-replacement Sweeteners, and Blood Sugar Control
Several sugar-replacement sweeteners are currently on the market, including saccharine (ex. Sweet'N Low), aspartame (ex. Equal), and sucralose (ex. Splenda).
- Trial name
- SIR (NCT01128829)
- Testing
- Water, Sucralose
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Type 2 Diabetes
Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes
High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications and death.
- Trial name
- NCT01845831
- Testing
- Sitagliptin, Basal Bolus, Metformin and Sitagliptin
- Where
- 5 sites in United States
- Volunteers
- 292 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 1
Improving Control and Reducing the Risk of Hypoglycemic Episodes in Type 1 Diabetes
The purpose of this study is to test two newly developed computer programs, Integrated Biobehavioral Monitoring and Feedback (IBMF) IBMF-1 and IBMF-2. The computer programs are considered experimental.
- Trial name
- BPK002 (NCT00315939)
- Testing
- Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1), Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Boris Kovatchev, PhD
Atherosclerosis, Cardiovascular Diseases
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and…
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension
- Trial name
- ACCORD (NCT00000620)
- Testing
- Anti-hyperglycemic Agents, Anti-hypertensive Agents
- Where
- 7 sites in United States, Canada
- Volunteers
- 10,251 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Type 2 Diabetes Mellitus
A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)
This study will assess the safety, tolerability and glucose-lowering efficacy of MK-0893 in participants with type 2 diabetes mellitus.
- Trial name
- NCT02004886
- Testing
- MK-0893, Metformin
- Volunteers
- 74 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes
Evaluation of The Postprandial Impact of Automated Priming Bolus for Full Closed Loop Insulin Delivery
The purpose of this study is to understand the impact of the automated priming boluses on the safety and feasibility of a new fully automated AP controller.
- Trial name
- Rocket-BPS (NCT05528770)
- Testing
- FCL+BPS, FCL
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Marc Breton
Obesity, Obesity, Abdominal
Vestibular Stimulation to Trigger Adipose Loss Clinical Trial
There is an ongoing and worsening problem with obesity in the developed, and much of the developing world. Although it has long been realized that Western diets that are rich in sugar and fat play an important role in this, it…
- Conditions
- Obesity, Obesity, Abdominal, Metabolic Syndrome, Weight Loss
- Trial name
- VeSTAL (NCT03138369)
- Testing
- Vestibular nerve stimulator
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Neurovalens Ltd.
Type 2 Diabetes Mellitus
Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin
This study will evaluate the efficacy and tolerability of saxagliptin compared to glimepiride in elderly patients with type 2 diabetes mellitus who have inadequate glycaemic control on metformin monotherapy.
- Trial name
- GENERATION (NCT01006603)
- Testing
- Saxagliptin, Glimepiride
- Where
- 131 sites in Austria, Denmark and 11 more
- Volunteers
- 957 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.